Advances in Biopharmaceutical Technology in China
back to index

 

Chapter 21:   Therapeutic Proteins in China


Zi-chun Hua and Jia-huang Li
Department of Biochemistry, Nanjing University
22 Hankou Road, Nanjing 210093, P. R. China
Phone and Fax: +86-25-83324605
Emails: zchua@nju.edu.cn and lijiah@nju.edu.cn

About the Authors:
Zichun Hua, Ph.D., is professor of Biochemistry at Nanjing University, and the director of the State Key Laboratory of Pharmaceutical Biotechnology since 1995. He received his Bachelor's Degree in 1986, Master's Degree in 1989, and Doctor's Degree in 1994 at Nanjing University. He received his postdoctoral training at the Wadsworth Research Center of New York State Health Department from 1994 to 1996. From 2000 to 2003, he was selected as Berkeley Scholar and did collaboration research at University of California at Berkeley. He has taught in Nanjing University since 1989, became associate professor in 1992 and full professor in 1995. Since 1999, he has been Deputy Dean of School of Life Sciences, Nanjing University. He has won the National Natural Science Award in 2000 (2nd Prize), the Science and Technology Progress Award of Ministry of Education in 1998 (1st Prize) and the Science and Technology Progress Award of JiangSu Province in 2004 (1st Prize). He has published 64 papers in international peer journals, been granted seven Chinese patents and one US patent. His research interests are: FADD, Caspase 8 and FLIP, their regulation in coupling cell proliferation and apoptosis; and Protein engineering of novel anti-angiogenic agents and anticoagulants
Jiahuang Li is a postdoctor in the State Key Laboratory of Pharmaceutical Biotechnology at Nanjing University. She received her Bachelor's Degree in 1996 and Doctor's Degree in 2004 at Nanjing University of Technology. Her research interests are: Folding/unfolding pathway of proteins; Computational drug design; and Analysis of interactions of protein-ligand, and protein-protein using molecule dynamics simulations

Abstract:
The R&D of protein medicine in China had a late beginning, but has developed quickly. This chapter summarizes the protein therapeutics being developed in China. It includes the production, R&D, current development of recombinant proteins and monoclonal antibodies in China. The related existing problems are objectively commented on. Protein therapeutics can be defined as the use of recombinant DNA techniques, monoclonal antibody techniques, cell engineering, fermentation engineering and other novel biotechnology approaches to research, develop and produce proteins for specific, desired therapeutic use. Development of biotechnology such as genetic engineering and protein engineering has accelerated the discovery of protein therapeutics and the identification of drug target candidates. Now protein drugs are widely used for treating diseases such as cancer, Hepatitis B, Hepatitis C, leukaemia, myocardial infarction, diabetes, organ transplantation etc.

back to index
Eric Langer
BioPlan Associates, Inc.
2275 Research Blvd, Suite 500
Rockville, MD 20850
Phone: 301-921-5979; Fax: 301-926-2455
E-Mail: info@bioplanassociates.com